Abstract: Methods for treatment of systemic lupus erythematosus (SLE” or “Lupus”) by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the following general structure and wherein X and Y are as defined herein.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
March 22, 2022
Assignee:
RECEPTOS LLC
Inventors:
Fiona Lorraine Scott, Kristen R. Taylor Meadows, Robert Peach
Abstract: An object of the present invention is to increase a protein content in milk of a lactating cow. When 5-ALA, an amino acid, or ALAs which are derivatives thereof or salts thereof, are mixed with a feed and administered to a lactating cow without being treated such as coating, a lactation yield remained substantially unchanged but the obtained milk had significantly high proportion (%) of proteins, particularly casein, when compared with milk collected from milk cows who had consumed a conventional feed.
Abstract: The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
March 15, 2022
Assignee:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventors:
Stuart Aaronson, Albino Troilo, Davide Esposito
Abstract: The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
March 1, 2022
Assignee:
RESQ Pharmaceuticals LLC
Inventors:
Balasingam Radhakrishnan, Ben Esque, Wei Lin, Andrew Xian Chen
Abstract: A opioid taper regimen, and its method of manufacture, for use in a method of opioid reduction leading to abstinence. Said regimen is administered within the range of 2 to 4 years, or more. The regimen comprises novel approaches to common problems encountered during tapers of low dose opioid addiction. The reduction regimen is generally linear; reduces the dosage level once per week; doses every six hours; reduces doses by steps in the range of about 0.001 to 0.0500 mg; has, near the end, ten weeks of doses of about 0.0025 mg buprenorphine q.i.d.; followed by four or more weeks of placebos. Instructions for manufacture of doses that differ by 0.0025 mg and 0.0050 mg buprenorphine are specified.
Abstract: The invention relates to oral pharmaceutical compositions comprising pimobendan pharmaceutically active compound. It also relates to a method for preparing the same uses thereof.
Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
Abstract: A method for the treatment of a coronavirus disease, including administering to a subject in need thereof of an anti-pathogenic compound, such that the anti-pathogenic compound is derived from an herbal extract.
Abstract: The present invention provides methods for inhibiting postoperative inflammatory conditions following ophthalmologic surgical procedures by administering intraocularly during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory agent and an alpha-1 adrenergic mydriatic agent, such as a liquid irrigation solution of ketorolac and phenylephrine.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
February 1, 2022
Assignee:
OMEROS CORPORATION
Inventors:
Gregory A. Demopulos, Vincent A. Florio
Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
Type:
Grant
Filed:
November 1, 2017
Date of Patent:
January 25, 2022
Assignee:
NOVARTIS AG
Inventors:
Robin Alec Fairhurst, Diana Graus Porta, Jacqueline Kinyamu-Akunda, Andreas Joerg Mahl, Luigi Manenti, Andreas Weiss, Armin Wolf, Kuno Wuersch
Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Abstract: A method of subcutaneous delivery of a drug or a therapeutic agent to a subject to treat a localized condition, the method including obtaining a liquid composition including the drug or the therapeutic agent dissolved in a tumescent solution, wherein the tumescent solution includes the drug or the therapeutic agent a vasoconstrictor; and a pharmaceutically acceptable carrier; and delivering a mass of the liquid composition subcutaneously to a localized tissue in the subject, wherein the drug or the therapeutic agent treats the localized condition in the localized tissue, wherein a concentration of the drug or the therapeutic agent subcutaneously delivered exceeds a concentration of the drug or the therapeutic agent that can be safely achieved by intravenous delivery, and wherein an amount of the drug or the therapeutic agent located at an outer boundary of the mass of fluid and available for absorption is less than an amount of the drug or the therapeutic agent located within a central portion of the mass of
Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
Abstract: The present invention relates to a composition for inhibiting the growth of cancer stem cells, which includes ciclesonide or a pharmaceutically acceptable salt thereof as an active ingredient, a pharmaceutical composition or food composition for inhibiting cancer metastasis, or treating or preventing cancer, which includes the composition, and the like. Ciclesonide of the present invention inhibits the growth of breast cancer cells and lung cancer cells, and inhibits the formation of breast cancer stem cells and lung cancer stem cells.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
December 7, 2021
Assignee:
JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: A method of treating a disease, condition or state characterized by an exacerbated immune response is disclosed. The method of treatment can include topoisomerase I inhibitors and pharmaceutical compositions comprising topoisomerase I inhibitors, which can be administered alone or in combination with another therapeutic agent. The method can be used to treat a range of diseases, disorders, conditions and states, including but not limited to sepsis, acute liver failure, and endotoxic and/or exotoxic shock. These diseases, disorders, conditions and states can be caused by a variety of microorganisms and/or portions of microorganisms including but not limited to Ebola virus, Lassa virus, Influenza virus, Legionella, lipopolysaccharide (LPS), and bacterial endotoxins/exotoxins.
Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful for use as prebiotic in a subject; for the modulation of the microbiota composition; for enhancing the population of good bacteria like Akkermansia muciniphila and for enhancing the efficacy of cancer immunotherapy of a subject. These compounds and compositions comprise at least one compound chosen from formula (I), (II), (III), (IV).
Abstract: Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.
Abstract: Methods of use, formulations, and devices for delivering therapeutic drugs locally to the region of the spleen are described herein. A method for treating sepsis and other inflammatory disease conditions can include inserting a drug delivery system inside the body, advancing the device to the spleen through the splenic artery, splenic vein or other blood vessel adjacent to the splenic nerves, or within a ligament associated with the spleen, such as the splenorenal or gastrosplenic ligaments.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
October 26, 2021
Assignee:
Tulavi Therapeutics, Inc.
Inventors:
Corinne Bright, Kondapavulur T. Venkateswara-Rao, Emily Stein
Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.